NEU neuren pharmaceuticals limited

Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-20

  1. 6,318 Posts.
    lightbulb Created with Sketch. 22692

    Study investigator, Dr. Jeffrey Neul, is featured today on NeurologyLive, discussing trofinetide as a potential treatment for Rett syndrome.


    NeurologyLive
    is a media platform for healthcare professionals treating neurological diseases.

    Dr. Neul points out that, not only is Lavender the first Phase 3 study that has met primary endpoints in Rett syndrome, but it is also one of the first times a successful phase 3 trial has been completed in any neurodevelopmental disorder.

    https://www.neurologylive.com/view/trofinetide-as-an-option-rett-syndrome-treatment

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$14.36
Change
-0.210(1.44%)
Mkt cap ! $1.787B
Open High Low Value Volume
$14.50 $14.56 $14.16 $3.192M 222.4K

Buyers (Bids)

No. Vol. Price($)
1 35 $14.33
 

Sellers (Offers)

Price($) Vol. No.
$14.40 2800 2
View Market Depth
Last trade - 16.10pm 14/07/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.